LIVE PRESENTATION LOBBY
HOME / LIVE WEBINARS

Welcome to our Live Webinar Page! From here you will be able to see when the next live presentation is set to take place and a countdown clock on when the room is to open. You will be able to join the webinar 5 minutes before the scheduled time. After the grey button "Room Closed" turns red, you will be able to watch the presentation.

The times below are displayed based on your computer time and time zone settings, which are currently set to:
SETTINGS CHECK
Please visit the link below to
Test Settings
Live October 22, 2020 - 19:00 UTC+2
0:00
Local Time
19:00 UTC+2
1603386000
Update on Bipolar Disorder
Pierre Blier  
Moderator
Canada
Allan Young  
Speaker
United Kingdom
Katherine Burdick  
Speaker
USA
Next Presentation Starts in
0
DAYS
0
HOURS
0
MINUTES
0
SECONDS
Not Yet Registered?
Click Here

Pre-Registered Attendees
Click Here
1603386000000
6
Update on Bipolar Disorder

Global Times
10:00 (Los Angeles), 13:00 (New York), 18:00 (London), 19:00 (Paris), 2:00, Oct 23 (Tokyo)

Speakers
Allan Young (United Kingdom)
Presentation Title: 
God’s Mood Stabiliser: Latest Data on Lithium

Katherine Burdick (USA)
Presentation Title: 
Cognitive Decline In Bipolar Disorder: Can We Prevent It?

Moderator
Pierre Blier (Canada)
Pierre Blier  
Moderator
Canada
Dr Pierre Blier is a Full Professor for the Departments of Psychiatry and Cellular & Molecular Medicine in the Faculty of Medicine at the University of Ottawa in Ottawa, Ontario, Canada, and the Director of the Mood Disorders Research Unit at The Royal’s Institute of Mental Health Research.Dr Blier is on the editorial boards of several journals and is the co-editor in chief for the Journal of Psychopharmacolgy. In addition to his extensive list of publications and lectures presented worldwide, Dr. Blier has contributed to several treatment guidelines for psychiatric disorders. Dr Blier has a basic research laboratory investigating how psychotropic medications work in the brain, he carries out investigator-initiated clinical studies, and treats patients with mood and anxiety disorders on a daily basis. Dr Blier received several awards for outstanding contributions to psychopharmacology including the Canada Research Chair in Psychopharmacology from the Government of Canada and is now a Fellow of the Royal Society of Canada (Life Sciences). He also serves on several committees, including the presidency elect of the CINP.
Allan Young  
Speaker
United Kingdom
Professor Allan Young is Chair of Mood Disorders and Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, where he is also interim Vice-Dean for Academic Psychiatry. Professor Young is the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) Cluster and Theme Lead in the Translational Therapeutics Cluster. He is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust, where he is also Consultant Psychiatrist and Head of the Affective Disorders Service. Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. He has received research grants from several funding agencies and has over 500 peer-reviewed publications, including several books about psychopharmacology and affective disorders. He is immediate past President of the International Society for Affective Disorders, past President of the British Association of Psychopharmacology and immediate past Chair of the Special Committee for Psychopharmacology of the Royal College of Psychiatrists. He is also a trustee of the patient and family charity Bipolar UK, and of the Drug Safety Research Unit (DSRU), internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Training Services for over 30 years.
Katherine Burdick  
Speaker
USA
Dr. Katherine E. Burdick is an Associate Professor of Psychology in Psychiatry at Harvard Medical School. She is the Director of the Mood and Psychosis Research Program and the Associate Vice Chair for Research in Psychiatry at Brigham and Women’s Hospital in Boston, MA. She has expertise in clinical and neurocognitive assessment across a range of patients with serious mental illness, including schizophrenia and bipolar disorder. Dr. Burdick obtained her Ph.D. in Clinical Neuropsychology from the City University of New York-The Graduate Center and completed her clinical internship and her postdoctoral fellowship at Yale University School of Medicine. She is a licensed clinical psychologist in the state of NY. Dr. Burdick has a strong track record of both federal and foundation funding, with a primary research focus on identifying persistent cognitive deficits in major psychiatric disorders, understanding their etiologies, and directly targeting them with treatment. She has collaborated on a wide range of projects including neuroimaging, genetics, and treatment trials in patients with bipolar disorder, schizophrenia, and major depression and has authored more than 130 peer-reviewed publications in this area.
Live November 5, 2020 - 16:00 UTC+2
0:00
Local Time
16:00 UTC+2
1604584800
News and Views in Anxiety Disorders
Siegfried Kasper  
Moderator
Austria
Katharina Domschke  
Speaker
Germany
David Baldwin  
Speaker
United Kingdom
Next Presentation Starts in
0
DAYS
0
HOURS
0
MINUTES
0
SECONDS
Not Yet Registered?
Click Here

Pre-Registered Attendees
Click Here
1604584800000
7
News and Views in Anxiety Disorders

Global Times
7:00 (Los Angeles), 10:00 (New York), 15:00 (London), 16:00 (Paris), 23:00 (Tokyo)

Speakers
Katharina Domschke (Germany)
Presentation Title: 
Epidemiology, Taxonomy and Etiology of Anxiety

David Baldwin (United Kingdom)
Presentation Title: 
Pharmacotherapy in anxiety disorders

Moderator
Siegfried Kasper (Austria)

Siegfried Kasper  
Moderator
Austria
Dr. Siegfried Kasper is Professor Emeritus of Psychiatry and former Chairman of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, Austria. Born in Salzburg, Austria, he was educated at the medical schools of the University of Innsbruck, Austria and the Universities of Freiburg and Heidelberg, Germany. Dr. Kasper gained clinical and research experience in psychiatry at the Central Institute of Mental Health, Mannheim, Germany, the Psychiatric Department of the University of Heidelberg, Germany, the Clinical Psychobiology Branch of the National Institute of Mental Health, Bethesda, Maryland/USA, and the Psychiatric Department of the University of Bonn, Germany; in neurology at the Neurological Department of the University of Heidelberg in Mannheim; and psychotherapeutic and psychoanalytic training at the Ausbildungsinstitut für Psychotherapie und Psychoanalyse in Heidelberg/Mannheim, Germany.Dr. Kasper published more than 600 in PubMed listed publications (Google: Citation Index: 47.641; Hirsch-Index: 104, i10-index: 652) and more than 250 books or book chapters, in various areas of psychiatry. He concentrates on the biological bases of mental disorders and their possible treatment approaches. Furthermore, he has conducted studies in psychopathological as well as clinical areas. Dr Kasper is a frequent national and international speaker and continues to be actively involved in research programmes studying depression, anxiety, psychosis, and dementia. Dr. Kasper serves/served on the executive committees and advisory boards of several national and international societies, such as the Austrian Association of Psychiatry, Psychotherapy and Psychosomatic (ÖGPP), the European College of Neuropsychopharmacology (ECNP) and the European Psychiatric Association (EPA). From 2005 to 2009 Dr. Kasper was President of the World Federation of Societies of Biological Psychiatry (WFSBP) and has been appointed as Honorary President of the WFSBP in 2013. He has been elected to the Executive Committee of the International College of Neuropsychopharmacology (CINP) for the period of 2012 to 2018 and is now President of this society. Moreover, Dr. Kasper is Chair of the World Psychiatric Association (WPA) Section of Pharmacopsychiatry. He is Founding President of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry (ÖGPB) and of the Austrian Society of Drug Safety in Psychiatry (ÖAMSP). Furthermore, he is a Honorary Member of the Czech Society of Neuropsychopharmacology, the Romanian Society of Neuropsychopharmacology, the Hungarian Psychiatric Association and a Fellow of the Royal College of Psychiatrists, UK, as well as of the Scandinavian College of Neuro-Psychopharmacology (SCNP) and of the Ukrainian Association of Psychiatry. He is a member of the European Academy of Sciences and Arts (EASA). Furthermore, he has been appointed as Honorary/Visiting Professor at the following universities: University of Hong Kong, China, in 2004; Universidad Andrés Bello, Santiago de Chile, Chile, 2014; Aino University in Osaka, Japan, 2015; Kolkata Institute of Psychiatry, Department of Health & Family Welfare, India in 2016; University of Hiroshima, Japan, in 2017 and Belgrade University School of Medicine, Serbia, in 2017.Dr. Kasper serves on the editorial boards of numerous learned journals, including The Lancet Psychiatry, CNS Spectrums, Journal of Affective Disorders, Pharmacopsychiatry, European Archives of Psychiatry and Neuroscience. He is Chief-Editor of the International Journal of Psychiatry in Clinical Practice and was Chief-Editor of the World Journal of Biological Psychiatry. He is Field Editor of the International Journal of Neuropsychopharmacology as well as Section Editor of the Annals of General Psychiatry.As a result of his research expertise he is the recipient of numerous national and international scientific and public awards and prizes and has been acknowledged with the Grand Decoration of Honor in Silver for Services to the Republic of Austria, the Austrian Cross of Honor for Science and Art, First Class, the Gold Medal for Meritorious Service to the Province of Vienna and received in 2019 the City of Vienna Award for Medical Science.
Katharina Domschke  
Speaker
Germany
Prof. Katharina Domschke, MA, MD, PhD, is Full Professor and Chair of the Dept. of Psychiatry and Psychotherapy, University of Freiburg, Germany, since 2016. Before that, she was Full Professor and Vice Chair of the Dept. of Psychiatry, University of Wuerzburg, Germany. Her clinical and teaching focus is on the treatment and prevention of anxiety, stress-related, affective and obsessive-compulsive disorders. Scientifically, Prof. Domschke is a renowned expert in genetics, epigenetics, imaging genetics and pharmacogenetics in the targeted treatment and prevention of anxiety, stress-related, affective and obsessive-compulsive disorders as reflected by to date over 290 publications in international journals and an h-index of 46. She has received funding from the EU, the German Research Foundation (DFG) and the German Ministry of Research and Education (BMBF) and is a full member of ACNP, ECNP, ISPG, SOBP and the German National Academy of Sciences Leopoldina. Prof. Domschke serves on the editorial boards of >10 international journals. Her work has been recognized by e.g. the WFSBP Research Award, the WPA Fellowship Award and the ECNP Fellowship Award.
David Baldwin  
Speaker
United Kingdom
David Baldwin is Professor of Psychiatry and Head of the Mental Health Group in the Clinical and Experimental Sciences Academic Unit of the Faculty of Medicine at the University of Southampton in the UK. He trained in medicine at Charing Cross Hospital Medical School, in psychiatry at St Mary's Hospital Medical School and the Maudsley Hospital, and in medical humanities at Birkbeck College. He is an Honorary Professor in the University of Cape Town in South Africa, and Visiting Professor at Shandong Mental Health Centre in Jinan, China. David is President-Elect of the British Association for Psychopharmacology, Past President of Depression Alliance, a Medical Patron of Anxiety UK, Editor-in-Chief of Human Psychopharmacology, and author of over 300 full articles in peer-reviewed scientific journals. He aims to improve clinical outcomes in mood and anxiety disorders: by investigating the role of neurobiological and psychological factors in causing and maintaining illness; through improving trial design when evaluating efficacy and tolerability of treatment interventions; by assessing the effectiveness and acceptability of treatment interventions in wider clinical practice; through identifying more accurately those patient groups at particular risk of poor outcomes. Through Southern Health NHS Foundation Trust, he offers a tertiary referral specialist service to patients with treatment-resistant conditions.
Technical Support
Please use the Live Support Button or the Chat Box below if you are having problems entering or viewing the presentation. Follow these standard checks first:
1. Close other applications & devices that may be using resources/bandwidth & restart your computer.
2. Restart your computer.
3. Try accessing the webinar through a different browser or download the app.
Live & Recording Details
The recording of the webinar will be made available shortly after the presentation is completed. Please visit the on-demand library to access the presentation once it has become available.